Interaction Between the Sodium-Glucose-Linked Transporter 2 Inhibitor Dapagliflozin and the Loop Diuretic Bumetanide in Normal Human Subjects.

ABSTRACT:

Background

Dapagliflozin inhibits the sodium-glucose-linked transporter 2 in the renal proximal tubule, thereby promoting glycosuria to reduce hyperglycemia in type 2 diabetes mellitus. Because these patients may require loop diuretics, and sodium-glucose-linked transporter 2 inhibition causes an osmotic diuresis, we evaluated the diuretic interaction between dapagliflozin and bumetanide.

Methods and results

Healthy subjects (n=42) receiving a fixed diet with ≈110 mmol·d^-1 of Na⁺ were randomized to bumetanide (1 mg·d^-1), dapagliflozin (10 mg·d^-1), or both for 7 days, followed by 7 days of both. There were no meaningful pharmacokinetic interactions. Na⁺ excretion increased modestly with the first dose of dapagliflozin (22

SUBMITTER: Wilcox CS 

PROVIDER: S-EPMC5850181 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature